Drug Profile
Research programme: regenerative therapeutics - NeoCytex
Alternative Names: NBI-18Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NeoCytex
- Class Small molecules
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO)
- 10 Jan 2011 Preclinical trials in CNS disorders in USA (PO)